323 related articles for article (PubMed ID: 34818767)
1. Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets - Magnifying global pandemic grieve and catastrophe begins.
Pushparaj K; Kuchi Bhotla H; Arumugam VA; Pappusamy M; Easwaran M; Liu WC; Issara U; Rengasamy KRR; Meyyazhagan A; Balasubramanian B
Sci Total Environ; 2022 Jan; 805():150355. PubMed ID: 34818767
[TBL] [Abstract][Full Text] [Related]
2. Mucormycosis, past and present: a comprehensive review.
Gupta I; Baranwal P; Singh G; Gupta V
Future Microbiol; 2023 Feb; 18():217-234. PubMed ID: 36970978
[TBL] [Abstract][Full Text] [Related]
3. Covid-19 and mucormycosis (Black Fungus): An epidemic within the pandemic.
Gambhir RS; Aggarwal A; Bhardwaj A; Kaur A; Sohi RK; Mehta S
Rocz Panstw Zakl Hig; 2021; 72(3):239-244. PubMed ID: 34553877
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
[TBL] [Abstract][Full Text] [Related]
5. Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.
Gurunathan S; Lee AR; Kim JH
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293381
[TBL] [Abstract][Full Text] [Related]
6. The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance.
Islam MR; Rahman MM; Ahasan MT; Sarkar N; Akash S; Islam M; Islam F; Aktar MN; Saeed M; Harun-Or-Rashid M; Hosain MK; Rahaman MS; Afroz S; Bibi S; Rahman MH; Sweilam SH
Environ Sci Pollut Res Int; 2022 Oct; 29(46):69341-69366. PubMed ID: 35986111
[TBL] [Abstract][Full Text] [Related]
7. Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease.
Rao C; R M
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443509
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 associated mucormycosis - An emerging threat.
Chao CM; Lai CC; Yu WL
J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 and mucormycosis superinfection: the perfect storm.
Al-Tawfiq JA; Alhumaid S; Alshukairi AN; Temsah MH; Barry M; Al Mutair A; Rabaan AA; Al-Omari A; Tirupathi R; AlQahtani M; AlBahrani S; Dhama K
Infection; 2021 Oct; 49(5):833-853. PubMed ID: 34302291
[TBL] [Abstract][Full Text] [Related]
10. Mucormycosis: An opportunistic pathogen during COVID-19.
Mahalaxmi I; Jayaramayya K; Venkatesan D; Subramaniam MD; Renu K; Vijayakumar P; Narayanasamy A; Gopalakrishnan AV; Kumar NS; Sivaprakash P; Sambasiva Rao KRS; Vellingiri B
Environ Res; 2021 Oct; 201():111643. PubMed ID: 34237335
[TBL] [Abstract][Full Text] [Related]
11. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
Rudrabhatla PK; Reghukumar A; Thomas SV
Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
[TBL] [Abstract][Full Text] [Related]
12. Surge of mucormycosis during the COVID-19 pandemic.
Dam P; Cardoso MH; Mandal S; Franco OL; Sağıroğlu P; Polat OA; Kokoglu K; Mondal R; Mandal AK; Ocsoy I
Travel Med Infect Dis; 2023; 52():102557. PubMed ID: 36805033
[TBL] [Abstract][Full Text] [Related]
13. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
[TBL] [Abstract][Full Text] [Related]
14. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic.
Bhanuprasad K; Manesh A; Devasagayam E; Varghese L; Cherian LM; Kurien R; Karthik R; Deodhar D; Vanjare H; Peter J; Michael JS; Thomas M; Samuel P; Varghese GM
Int J Infect Dis; 2021 Oct; 111():267-270. PubMed ID: 34450284
[TBL] [Abstract][Full Text] [Related]
15. Mucormycosis in COVID-19 patients.
Sundaram N; Bhende T; Yashwant R; Jadhav S; Jain A
Indian J Ophthalmol; 2021 Dec; 69(12):3728-3733. PubMed ID: 34827032
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 associated mucormycosis (CAM) in India: a formidable challenge.
Rao VUS; Arakeri G; Madikeri G; Shah A; Oeppen RS; Brennan PA
Br J Oral Maxillofac Surg; 2021 Nov; 59(9):1095-1098. PubMed ID: 34507870
[TBL] [Abstract][Full Text] [Related]
17. Mucor in a Viral Land: A Tale of Two Pathogens.
Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
[TBL] [Abstract][Full Text] [Related]
18. Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics.
Gupta G; S R; Singh Y; Thangavelu L; Singh SK; Dureja H; Chellappan DK; Dua K
Drug Dev Res; 2021 Nov; 82(7):880-882. PubMed ID: 34323298
[TBL] [Abstract][Full Text] [Related]
19. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
[TBL] [Abstract][Full Text] [Related]
20. Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
Sharma R; Kumar P; Rauf A; Chaudhary A; Prajapati PK; Emran TB; Gonçalves Lima CM; Conte-Junior CA
Front Cell Infect Microbiol; 2022; 12():937481. PubMed ID: 35923801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
